Navigation Links
Fibrillation in Medical Technology

FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)

... (FDA) to treat patients with non-permanent atrial fibrillation (AF). As demonstrated in the ATHENA trial, ... reviewing new drug applications. Atrial fibrillation is the leading cause of hospitalization for ... fold) in recent years in the U.S. Atrial fibrillation is a complex disease that increases the risk of ...

New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation

... or death by 24 percent in patients with atrial fibrillation - PARIS, Feb. 11 /PRNewswire-FirstCall/ -- ... vs. 39.4%, p<0.001) in patients with atrial fibrillation (AF)/atrial flutter (AFL) or a recent history of these conditions. Atrial fibrillation is the leading cause of hospitalization for ...

New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation

... -- Patients with non-valvular atrial fibrillation receiving either 30 mg or 60 mg once-daily dose ... evaluating an oral Factor Xa inhibitor in atrial fibrillation patients. DU-176b is being developed solely by ... A total of 1,146 patients with atrial fibrillation with a CHADS2 index >/= 2 were enrolled in the ...

Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation

... with Factor Xa Next Generation in Atrial fibrillation (ENGAGE-AF TIMI 48), will compare DU-176b with ... of clotting or stroke in patients with atrial fibrillation other than the current standard of care, ... cardiovascular portfolio." About Atrial fibrillation ...

Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation

... of hospital days by 28% in patients with atrial fibrillation or flutter NEW ORLEANS, Nov. 11 ... Fewer patients developed permanent atrial fibrillation during the study in the dronedarone group - 178 ... groups. About Atrial Fibrillation Atrial fibrillation (AF) is a common heart arrhythmia in which ...

Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation

... the risk of stroke by 34% in patient with atrial fibrillation or atrial flutter already adequately ... 70 stroke events respectively; p=0.027) in atrial fibrillation / atrial flutter patients adequately treated by ... to a paradigm shift in the management of atrial fibrillation as it is the first time that an anti-arrhythmic ...

Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation

... the Risk of Stroke by 34% in Patients With Atrial fibrillation or Atrial Flutter Already Adequately Treated by ... 70 stroke events respectively; p=0.027) in atrial fibrillation / atrial flutter patients adequately treated by ... to a paradigm shift in the management of atrial fibrillation as it is the first time that an anti-arrhythmic ...

Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies

... paroxysmal atrial fibrillation. Paroxysmal atrial fibrillation (PAF) is characterized by a rapid rhythm of the ... drug therapy and were free of atrial fibrillation 9 months (+/- 2 months) following a single ... so many patients with paroxysmal atrial fibrillation are visiting their healthcare provider for ...

Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation

... in patients with Atrial Fibrillation." Atrial fibrillation is a major cause of hospitalization and ... congestive heart failure. Furthermore atrial fibrillation considerably impairs patients' lives, mainly ... prevention and treatment of patients with atrial fibrillation or atrial flutter. Dronedarone is a ...

Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times

... positive findings about its novel atrial fibrillation catheter ablation system were presented at ... considerably shortened procedure times." Atrial fibrillation (AF) is a common and devastating cardiac ... to helping individuals suffering from atrial fibrillation and other cardiac arrhythmias. Working in concert ...

Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients

... the advanced ablation system to treat atrial fibrillation (AF) patients in commercial procedures throughout ... the Center for the Advanced Management of Atrial fibrillation at the Brigham and Women's Hospital in Boston. ... and permanent AF populations." Atrial fibrillation is a common and devastating cardiac rhythm ...

ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress

... conference entitled, "New Perspectives in Atrial fibrillation Management" chaired by John Camm, Professor of ... ERATO, and the ongoing DIONYSOS trial. Atrial fibrillation is a major cause of hospitalization and ... congestive heart failure. About Atrial fibrillation / Flutter ...

ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress

... conference entitled "New Perspectives in Atrial fibrillation Management" chaired by John Camm, Professor of ... between the 2 study groups. Atrial fibrillation is a major cause of hospitalisation and ... and the ongoing DIONYSOS trial. About Atrial fibrillation / Flutter ...

Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation

... therapy for the treatment of patients with atrial fibrillation or atrial flutter, decreased the risk of ... and antithrombotic drugs, in patients with atrial fibrillation or atrial flutter. Multaq(R) also significantly ... of atrial fibrillation management. For atrial fibrillation patients, who together with their physicians ...

Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study

... is the largest stroke prevention in atrial fibrillation trial conducted to date, with 18,114 patients, in ... INR 2.0-3.0) in patients with non-valvular atrial fibrillation who are at moderate-to-high risk of stroke. ... our original expectations by far." Atrial fibrillation is the most common sustained cardiac ...

FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial

... of Chronic Atrial fibrillation Patients CARLSBAD, Calif., Jan. 16 /PRNewswire/ ... for interventional treatment of chronic atrial fibrillation (AF). Approval from the US Food and Drug ... in the US. About Atrial Fibrillation Atrial fibrillation remains the most commonly diagnosed ...

ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia

... effect in preventing atrial fibrillation and life threatening ventricular arrhythmia, ... New Data on Bucindolol in Atrial fibrillation and Ventricular Arrhythmia Data from the Phase 3 ... clinically important arrhythmic conditions-atrial fibrillation (AF) and life threatening ventricular arrhythmias ...

Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset

... (sinus rhythm, or SR) in patients with atrial fibrillation (AF) treated within 48 hours of the onset of ... vs. 1.7 percent, respectively). About Atrial fibrillation Atrial fibrillation (AF) is an interruption of the normal sinus ...

CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation

... our lead over other companies conducting atrial fibrillation ablation pivotal trials and brings us one step ... of approval for the treatment of atrial fibrillation in 2009." Helen Barold, M.D. Chief Medical ... lead time over other companies conducting atrial fibrillation ablation pivotal trials, ability of obtain FDA ...

Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

... inhibitor - provides insights into why patients with non-valvular atrial fibrillation (AF) receiving edoxaban once daily (QD) experienced fewer bleeding events ... study, Effective Anticoagulation with Factor Xa Next Generation in Atrial fibrillation (ENGAGE-AF), is comparing edoxaban with warfarin (INR2-3) for the ...

New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation

... the procedure reduces the chance that patients will experience atrial fibrillation over the long term. The report, which compared radiofrequency ... at risk for heart failure, blood clots, or stroke. Patients with atria fibrillation are typically treated with medication first, but medicines only work for ...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... conditions can elevate a person's risk of clotting, including atrial fibrillation (an abnormal heart rhythm), previous heart attack, long periods of ... dose of warfarin is given. A total of 1,146 patients with atrial fibrillation were randomized to receive either one of four fixed-dose regimens of ...

Atrial Fibrillation Found to be Common in Patients With Atherothrombosis, Increases Risk of Cardiovascular Death, Heart Attack and Stroke

... - Large, International REACH Registry Also Shows Many Patients With Atrial fibrillation are Undertreated With Antiplatelet and Anticoagulant Therapies A significant portion of patients with atherothrombosis also have atrial fibrillation (AF), greatly increasing their risk for cardiovascular death, heart attack ...

American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation

... persistent (responsive to cardioversion) or permanent (continuous atrial fibrillation with cardioversion proven or deemed ineffective). In patients with ... decreased ventricular rate during a first recurrence of atrial fibrillation in paroxysmal and persistent AF patients. The well- proven ...

HUYA Bioscience Int'l Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China

... Phase I studies completed in China, HBI-3000 was well tolerated. Atrial fibrillation (AF) is a serious type of arrhythmia found in approximately 2.2 million ... being developed and investigated for use as IV treatment of atrial fibrillation with clinical trials expected to begin in early 2009. "This is a ...

Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm

... that 75 of the 145 (51.7%) KYNAPID patients in the short-duration atrial fibrillation (AF) group (3 hours to 7 days) converted to sinus rhythm within 90 minutes ... for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our ...

ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line

... technique developed by Dr. James L. Cox in the 1980s to treat atrial fibrillation (AF) with a high rate of long-term success. (Logo: ... the ATS CryoMaze products the source for the surgical treatment of atrial fibrillation through less-invasive approaches. The team's focus is on developing tools ...

Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation

... tedisamil as a treatment for rapid conversion of recent onset atrial fibrillation to normal sinus rhythm (NSR). The Committee voted against approval of ... FDA on or before January 19, 2008. About Atrial Fibrillation Atrial fibrillation (AFib) is an abnormal heart rhythm, known as a cardiac arrhythmia, ...

Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery

... to normal heart rhythm (sinus rhythm, or SR) in patients with atrial fibrillation (AF) following coronary artery bypass graft (CABG) or valvular surgeries. ... were no deaths or cases of torsade de pointes. About Atrial fibrillation AF is an interruption of the normal sinus rhythm (arrhythmia) of ...

CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway

... patients with symptomatic paroxysmal atrial fibrillation". About Atrial fibrillation AF is a potentially serious cardiac arrhythmia typically ... Society, The Task Force on Catheter and Surgical Ablation of Atrial fibrillation wrote: "There is a consensus among the Task Force that the primary ...

deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke

... prevention of common diseases. Through its CLIA-registered laboratory, deCODE offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and ...

deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia

... prevention of common diseases. Through its CLIA-registered laboratory, deCODE offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and ...

deCODE Receives California Clinical Laboratory License

... prevention of common diseases. Through its CLIA-registered laboratory, deCODE is offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and ...

Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting

... LAA Closure Technology is intended as an alternative to warfarin therapy for patients with non-valvular atrial fibrillation. Patients with atrial fibrillation (a heart condition which causes the upper chambers of the heart to beat too rapidly) are at a significantly greater risk of having a stroke due to ...

deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention

... prevention of common diseases. Through its CLIA-registered laboratory, deCODE is offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and ...

A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer

... prevention of common diseases. Through its CLIA-registered laboratory, deCODE is offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and ...

Major deCODE-led Study Underscores Role of the Brain in Obesity

... prevention of common diseases. Through its CLIA-registered laboratory, deCODE is offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE ...

deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders

... DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE ...

deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer

... DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for prostate cancer; and deCODE Glaucoma(TM) for a major type of glaucoma. deCODE is ...

deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia

... DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for prostate cancer; and deCODE Glaucoma(TM) for a major type of glaucoma. deCODE is ...
Other Contents
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62/113114 for DISTRIBUTED METHOD ... The patent further establishes NXT-ID,s position in ... intellectual property portfolio the ability for multiple devices to ...
(Date:2/10/2015)... -- Alere Inc. (NYSE: ALR), a global leader in ... quarter ended December 31, 2014. Namal ... said, "We made substantial progress in the fourth ... in rapid diagnostics and delivering against our financial ... early January enabled us to substantially reduce our ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33
(Date:2/28/2015)... February 28, 2015 In recent years Medical ... of practicing physicians as a way for them to expand ... regarding Cannabis as medicine. Since the FDA still lists Cannabis ... resources available to licensed physicians that can help guide ... Dr. Deborah Malka in Santa Cruz, CA is a ...
(Date:2/28/2015)... February 28, 2015 In a recent ... of Game Change Athlete Development Services ... about the benefits of athlete development and player engagement ... the unique challenges that athletes face and how off-field ... success. , Fletcher became involved in athlete development issues ...
(Date:2/28/2015)... 28, 2015 With their commitment to ... added an additional exercise to their already robust library ... is most commonly known as, is often performed on ... are executed in a relatively safe manner and can ... levels. The full description of “Rope Pulls” is located ...
(Date:2/28/2015)... Oregon (PRWEB) February 28, 2015 The ... Oregon, is offering a new special. Throughout all ... relines. , This service can ... sleep problems and pain. Patients may notice certain symptoms ... need relining. These symptoms include: , 1.    Pain, clicking, ...
(Date:2/28/2015)... February 28, 2015 Mew and Company, ... that they now provide business consulting services in addition ... corporate tax planning and succession planning. Company finances are ... experienced professionals. On top of this, complex Canadian tax ... corporate accounting. As a result, Mew and Company works ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2
Other TagsOther Tags